Literature DB >> 19074414

Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells.

Simon Lord-Dufour1, Ian B Copland, Louis-Charles Levros, Martin Post, Abhirup Das, Chaitan Khosla, Jacques Galipeau, Eric Rassart, Borhane Annabi.   

Abstract

Mesenchymal stromal cell (MSC) markers are expressed on brain tumor-initiating cells involved in the development of hypoxic glioblastoma. Given that MSCs can survive hypoxia and that the glucose-6-phosphate transporter (G6PT) provides metabolic control that contributes to MSC mobilization and survival, we investigated the effects of low oxygen (1.2% O(2)) exposure on G6PT gene expression. We found that MSCs significantly expressed G6PT and the glucose-6-phosphatase catalytic subunit beta, whereas expression of the glucose-6-phosphatase catalytic subunit alpha and the islet-specific glucose-6-phosphatase catalytic subunit-related protein was low to undetectable. Analysis of the G6PT promoter sequence revealed potential binding sites for hypoxia inducible factor (HIF)-1alpha and for the aryl hydrocarbon receptor (AhR) and its dimerization partner, the AhR nuclear translocator (ARNT), AhR:ARNT. In agreement with this, hypoxia and the hypoxia mimetic cobalt chloride induced the expression of G6PT, vascular endothelial growth factor (VEGF), and HIF-1alpha. Gene silencing of HIF-1alpha prevented G6PT and VEGF induction in hypoxic MSCs whereas generation of cells stably expressing HIF-1alpha resulted in increased endogenous G6PT gene expression. A semisynthetic analog of the polyketide mumbaistatin, a potent G6PT inhibitor, specifically reduced MSC-HIF-1alpha cell survival. Collectively, our data suggest that G6PT may account for the metabolic flexibility that enables MSCs to survive under conditions characterized by hypoxia and could be specifically targeted within developing tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19074414      PMCID: PMC2728688          DOI: 10.1634/stemcells.2008-0855

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  48 in total

1.  PROMO: detection of known transcription regulatory elements using species-tailored searches.

Authors:  Xavier Messeguer; Ruth Escudero; Domènec Farré; Oscar Núñez; Javier Martínez; M Mar Albà
Journal:  Bioinformatics       Date:  2002-02       Impact factor: 6.937

2.  MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival.

Authors:  Jean-Christophe Currie; Simon Fortier; Asmaa Sina; Jacques Galipeau; Jian Cao; Borhane Annabi
Journal:  J Biol Chem       Date:  2007-01-17       Impact factor: 5.157

3.  Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b.

Authors:  Rosanna Leuzzi; Gábor Bánhegyi; Tamás Kardon; Paola Marcolongo; Piero-Leopoldo Capecchi; Hans-Joerg Burger; Angelo Benedetti; Rosella Fulceri
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

4.  Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice.

Authors:  W H Yiu; C-J Pan; M Allamarvdasht; S Y Kim; J Y Chou
Journal:  Gene Ther       Date:  2006-09-28       Impact factor: 5.250

Review 5.  Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.

Authors:  Janice Yang Chou; Dietrich Matern; Brian C Mansfield; Yuan-Tsong Chen
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

6.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

7.  Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision.

Authors:  Anissa Belkaid; Simon Fortier; Jian Cao; Borhane Annabi
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

8.  Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells.

Authors:  R M Dwyer; S M Potter-Beirne; K A Harrington; A J Lowery; E Hennessy; J M Murphy; F P Barry; T O'Brien; M J Kerin
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

Review 9.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

10.  Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines.

Authors:  Tobias Birnbaum; Julia Roider; Christoph J Schankin; Claudio S Padovan; Christian Schichor; Roland Goldbrunner; Andreas Straube
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.506

View more
  18 in total

1.  Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.

Authors:  Caryn S Gonsalves; Chen Li; Marthe-Sandrine Eiymo Mwa Mpollo; Vinod Pullarkat; Punam Malik; Stanley M Tahara; Vijay K Kalra
Journal:  Biochem J       Date:  2015-04-16       Impact factor: 3.857

Review 2.  Environmental preconditioning rejuvenates adult stem cells' proliferation and chondrogenic potential.

Authors:  Ming Pei
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

Review 3.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Increased oxygen consumption and OXPHOS potential in superhealer mesenchymal stem cells.

Authors:  Curtis C Hughey; Maria P Alfaro; Darrell D Belke; Jeffery N Rottman; Pampee P Young; David H Wasserman; Jane Shearer
Journal:  Cell Regen (Lond)       Date:  2012-06-28

5.  Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells.

Authors:  Alain Zgheib; Sylvie Lamy; Borhane Annabi
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

6.  Pre-culturing human adipose tissue mesenchymal stem cells under hypoxia increases their adipogenic and osteogenic differentiation potentials.

Authors:  M G Valorani; E Montelatici; A Germani; A Biddle; D D'Alessandro; R Strollo; M P Patrizi; L Lazzari; E Nye; W R Otto; P Pozzilli; M R Alison
Journal:  Cell Prolif       Date:  2012-06       Impact factor: 6.831

Review 7.  Effect of hypoxia on human adipose-derived mesenchymal stem cells and its potential clinical applications.

Authors:  Jane Ru Choi; Kar Wey Yong; Wan Kamarul Zaman Wan Safwani
Journal:  Cell Mol Life Sci       Date:  2017-02-21       Impact factor: 9.261

8.  Benefits of hypoxic culture on bone marrow multipotent stromal cells.

Authors:  Chih-Chien Tsai; Tu-Lai Yew; Der-Chi Yang; Wei-Hua Huang; Shih-Chieh Hung
Journal:  Am J Blood Res       Date:  2012-10-20

9.  Glucotoxicity induces glucose-6-phosphatase catalytic unit expression by acting on the interaction of HIF-1α with CREB-binding protein.

Authors:  Amandine Gautier-Stein; Maud Soty; Julien Chilloux; Carine Zitoun; Fabienne Rajas; Gilles Mithieux
Journal:  Diabetes       Date:  2012-07-10       Impact factor: 9.461

10.  Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.